Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-10-09
2007-10-09
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S326000, C530S388250, C530S387100, C530S389300
Reexamination Certificate
active
11093103
ABSTRACT:
An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
REFERENCES:
patent: 4395396 (1983-07-01), Eibl et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5932706 (1999-08-01), Mertens
patent: 6624295 (2003-09-01), Adams et al.
patent: 2005/0058640 (2005-03-01), Kerschbaumer et al.
patent: WO95/13300 (1995-05-01), None
patent: WO97/26010 (1997-07-01), None
patent: WO99/01476 (1999-01-01), None
Bolton-Maggs et al., The Lancet, 2003, 361:1801-1809.
Stedman's Medical Dictionary, 27thedition, copyright 2000, “diathesis”, one page.
Stedman's Medical Dictionary, 27th edition, copyright 2000, “Hemorrhagic”, one page.
Ames, R.S. et al., Conversion of Murine Febs Isolated From a Combinatorial Phage Display Library to Full Length Immunoglobulins,J. Immunol. Methods, pp. 177-186 (1995).
Bajaj, S.P. et al., A Monoclonal Antibody to Factor IX That Inhibits the Factor VIII:Ca Potentiation of Factor X Activation,The Journal of Biological Chemistry, 260(21), pp. 11574-11580 (1985).
Bessos, H., et al., The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX,Thrombosis Research, 40, pp. 863-867 (1985).
Cao, Y. et al., Bispecific Antibodies as Novel Bioconjugates,Bioconjugate Chemistry, 9(6); pp. 635-644 (1998).
Cohen, F.E., et al., The Combinatorial Approach,Protein Structure Prediction—A Practical Approach(Ed. M.J.E. Sternberg), Oxford University Press, Ch. 9, pp. 207-227 (1996).
Engelhardt, O., et al., Two-Step Cloning of Antibody Variable Domains in a Phage Display Vector,Biotechniques, 17, p. 44-46 (1994).
Esser, C., et al., Immunoglobulin Class Switching: Molecular and Cellular Analysis,Annu. Rev. Immunol., 8, p. 717-735 (1990).
Evan, G.I., et al., Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product,Mol. Cell. Biol., 5(12), p. 3610-3616 (1985).
Fay, P.J., et al., Factor VIIIa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site,Journal of Biological Chemistry, 269(32), p. 20522-20527 (1994).
Frazier, D., et al., Mapping of Monoclonal Antibodies to Human Factor IX,Blood, 74(3), p. 971-977 (1989).
Gao, C., et al., Making Artificial Antibodies: A Format for Phage Display of Combinatorial Heterodimeric Arrays,Proc. Natl. Acad. Sci., 96, p. 6025-6030 (1999).
Grassy, G., et al., Computer-Assisted Rational Design of Immunosuppressive Compounds,Nature Biotechnology, 16, p. 748-752 (1998).
Greer, J., et al., Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design,Journal of Medicinal Chemistry, 37(8), p. 1035-1054 (1994).
Harlow, E., et al., 2. Antibody Molecules,Antibodies—A Laboratory Manual; pp. 7-22 (1988).
Harlow, E., et al., 3. Antibody-Antigen Interactions,Antibodies—A Laboratory Manual; p. 23-35 (1988).
Harlow, E., et al., 6. Monoclonal Antibodies,Antibodies—A Laboratory Manual; p. 139-243 (1988).
Hochuli, E., et al., Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent,Biotechnology, 6, p. 1321-1325 (1988).
Huston, J.S., et al., Medical Applications of Single-Chain Antibodies,Intern. Rev. Immunol., 10, p. 195-217 (1993).
Jones, D.T., et al., Protein Folds and Their Recognition from Sequence,Protein Structure Prediction—A Practical Approach(Ed. M.J.E. Sternberg), Oxford University Press, Ch. 8, p. 174-206 (1996).
Jones, P.T., et al., Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,Nature, 321, p. 522-525 (1986)
Jorquera, J.I., et al., Synthetic Peptides Derived from Residues 698 to 710 of Factor VIII Inhibit Factor IXa Activity,Circulation, 86, Abstract No. 2725, p. I-685 (1992).
Karpen, M.E., et al., Modelling Protein Conformation by Molecular Mechanics and Dynamics,Protein Structure Prediction—A Practical Approach(Ed. M.J.E. Sternberg), Oxford University Press, Ch. 10, p. 229-261 (1996).
Kemp, D.S., Peptidomimetics and the Template Approach to Nucleation of B-sheets and a-helices in Peptides,TIBTECH, 8, p. 249-255 (1990).
Kerschbaumer, R.J., et al., pDAP2: A Vector for Construction of Alkaline Phosphatase Fusion-Proteins,Immunotechnology, 2, p. 145-150 (1996).
Kerschbaumer, R.J. et al., Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme-Linked Immunosorbent Assay,Analytical Biochemistry, 249, p. 219-227 (1997).
Lane, R.D., A Short-Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody-Secreting Hybridomas,Journal of Immunological Methods, 81, p. 223-227 (1985).
Lenting, P.J., et al., The Sequence Glu1811-Lys1818of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX,Journal of Biological Chemistry, 271(4), p. 1935-1940 (1996).
Liles, D.K., et al, The Factor VIII Peptide Consisting of Amino Acids 698 to 712 Enhances Factor IXa Cleavage of Factor X,Blood, 90(1), Abstract No. 2054, p. 463a (1997).
Lin, H-F., et al, A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B,Blood, 90(10), p. 3962-3966 (1997).
Malik, P., et al., Multiple Display of Foreign Peptide Epitopes on Filamentous Bacteriophage Virions,Phage Display of Peptides and Proteins(Ed. B. K. Kay et al.), Academic Press, p. 127-139 (1996).
Mann, K.G., et al., Surface-Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes,Blood, 76(1), p. 1-16 (1990).
Mikaelsson, M., et al., Standardization of VIII:C Assays: A Manufacturer's View,Scandinavian Journal of Haematology(Ed. Nilsson et al.), 33, p. 79-86 (1984).
Nilsson, I.M. et al., Induction of Split Tolerance and Clinical Cure in High-Responding Hemophiliacs with Factor IX Antibodies,Proc. Natl. Acad. Sci. USA, 83, p. 9169-9173 (1986).
Persic, L., et al., An Integrated Vector System For The Eukaryotic Expression of Antibodies or Their Fragments After Selection From Phase Display Libraries,Gene, p. 9-18 (1997).
Pluckthun, A., et al., New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments,Immunotechnology, 3, p. 83-105 (1997).
Raag, R., et al., Single-Chain Fvs,FASEB Journal, 9(1), pp. 73-80 (1995).
Rees, A.R., et al., Antibody Combining Sites: Structure and Prediction,Protein Structure Prediction-A Practical Approach(Ed. M.J.E. Sternberg), Oxford University Press, Ch. 7, p. 141-172 (1996).
Roitt, I.M., et al., Molecules which Recognize Antigen,Immunology, 2ndEdition, p. 5.1-5.11 (1989).
Sadler, J.E., et al., Hemophilia A, Hemophilia B, and von Willebrand's Disease,The Molecular Basis of Blood Diseases(Ed. G. Stamatoyannopoulos et al.), p. 575-630 (1987).
Vaughan, T.J., et al., Human Antibodies By Design,Nature Biotechnology, p. 535-539 (1998).
Winter, G., et al., Making Antibodies by Phage Display Technology,Annu. Rev. Immunol., 12, p. 433-455 (1994).
Zhong, D., et al., Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX,Blood, 92(1), p. 136-142 (1998).
Dorner Friedrich
Falkner Falko-Guenter
Kerschbaumer Randolf
Scheiflinger Friedrich
Schwarz Hans-Peter
Baxter Aktiengesellschaft
Ewoldt G. R.
Szperka Michael
Townsend and Townsend / and Crew LLP
LandOfFree
Factor IX/factor IXa activating antibodies and antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor IX/factor IXa activating antibodies and antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor IX/factor IXa activating antibodies and antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3901029